Abstract
Kinase inhibitors are important cancer drugs, but they tend to display limited target specificity, and their target profiles are often challenging to rationalize in terms of molecular mechanism. Here we report that the clinical kinase inhibitor bosutinib recognizes its kinase targets by engaging a pair of conserved structured water molecules in the active site and that many other kinase inhibitors share a similar recognition mechanism. Using the nitrile group of bosutinib as an infrared probe, we show that the gatekeeper residue and one other position in the ATP-binding site control access of the drug to the structured water molecules and that the amino acids found at these positions account for the kinome-wide target spectrum of the drug. Our work highlights the importance of structured water molecules for inhibitor recognition, reveals a new role for the kinase gatekeeper and showcases an effective approach for elucidating the molecular origins of selectivity patterns.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cohen, P. Protein kinases–the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309–315 (2002).
Druker, B.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
Wong, S. et al. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc. Natl. Acad. Sci. USA 101, 17456–17461 (2004).
Demetri, G.D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–480 (2002).
Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621–637 (2005).
Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329–336 (2005).
Liu, Y. & Gray, N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358–364 (2006).
Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938–1942 (2000).
Cortes, J.E. et al. Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). J. Clin. Oncol. 28, 487–492 (2010).
Campone, M. et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann. Oncol. 23, 610–617 (2012).
Blencke, S. et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691–701 (2004).
Liu, Y. et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 6, 671–678 (1999).
Gorre, M.E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).
Dar, A.C. & Shokat, K.M. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem. 80, 769–795 (2011).
Davis, M.I. et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1046–1051 (2011).
Redaelli, S. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 27, 469–471 (2009).
Levinson, N.M. & Boxer, S.G. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One 7, e29828 (2012).
Shan, Y. et al. A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc. Natl. Acad. Sci. USA 106, 139–144 (2009).
Hubbard, S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572–5581 (1997).
Russo, A.A., Jeffrey, P.D. & Pavletich, N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 3, 696–700 (1996).
Lowe, E.D. et al. The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J. 16, 6646–6658 (1997).
Madhusudan, Akamine, P., Xuong, N.H. & Taylor, S.S. Crystal structure of a transition state mimic of the catalytic subunit of cAMP-dependent protein kinase. Nat. Struct. Biol. 9, 273–277 (2002).
Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275–282 (2002).
Golovin, A. & Henrick, K. MSDmotif: exploring protein sites and motifs. BMC Bioinformatics 9, 312 (2008).
Meijer, L. et al. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7, 51–63 (2000).
Kothe, M. et al. Selectivity-determining residues in Plk1. Chem. Biol. Drug. Des. 70, 540–546 (2007).
Hughes, S. et al. Crystal structure of human CDC7 kinase in complex with its activator DBF4. Nat. Struct. Mol. Biol. 19, 1101–1107 (2012).
Davies, T.G. et al. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 9, 745–749 (2002).
Tahtouh, T. et al. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J. Med. Chem. 55, 9312–9330 (2012).
Liddle, J. et al. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. Bioorg. Med. Chem. Lett. 21, 6188–6194 (2011).
Matsuoka, D. & Nakasako, M. Probability distributions of hydration water molecules around polar protein atoms obtained by a database analysis. J. Phys. Chem. B 113, 11274–11292 (2009).
Atwell, S. et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279, 55827–55832 (2004).
Ladbury, J.E. Just add water! The effect of water on the specificity of protein-ligand binding sites and its potential application to drug design. Chem. Biol. 3, 973–980 (1996).
Reimers, J.R. & Hall, L.E. The solvation of acetonitrile. J. Am. Chem. Soc. 121, 3730–3744 (1999).
Choi, J.H., Oh, K.I., Lee, H., Lee, C. & Cho, M. Nitrile and thiocyanate IR probes: quantum chemistry calculation studies and multivariate least-square fitting analysis. J. Chem. Phys. 128, 134506 (2008).
Weiss, E.L., Bishop, A.C., Shokat, K.M. & Drubin, D.G. Chemical genetic analysis of the budding-yeast p21-activated kinase Cla4p. Nat. Cell Biol. 2, 677–685 (2000).
Stamos, J., Sliwkowski, M.X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265–46272 (2002).
Gajiwala, K.S. et al. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 21, 209–219 (2013).
Park, J.H., Liu, Y., Lemmon, M.A. & Radhakrishnan, R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem. J. 448, 417–423 (2012).
Hennequin, L.F. et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 49, 6465–6488 (2006).
Poornima, C.S. & Dean, P.M. Hydration in drug design. 1. Multiple hydrogen-bonding features of water molecules in mediating protein-ligand interactions. J. Comput. Aided Mol. Des. 9, 500–512 (1995).
Fried, S.D., Bagchi, S. & Boxer, S.G. Measuring electrostatic fields in both hydrogen-bonding and non-hydrogen-bonding environments using carbonyl vibrational probes. J. Am. Chem. Soc. 135, 11181–11192 (2013).
Seeliger, M.A. et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 14, 3135–3139 (2005).
Joseph, R.E. & Andreotti, A.H. Bacterial expression and purification of interleukin-2 tyrosine kinase: single step separation of the chaperonin impurity. Protein Expr. Purif. 60, 194–197 (2008).
Steichen, J.M. et al. Structural basis for the regulation of protein kinase A by activation loop phosphorylation. J. Biol. Chem. 287, 14672–14680 (2012).
Leslie, A.G.W. & Powel, H.R. Evolving Methods for Macromolecular Crystallography. 245, 41–51 ISBN 978-1-4020-6314-5 (2007).
CCP4. The CCP4 Suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994).
Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta. Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
Seeliger, M.A. et al. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 69, 2384–2392 (2009).
Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
Steiner, T. The hydrogen bond in the solid state. Angew. Chem. Int. Ed. Engl. 41, 49–76 (2002).
Bachrach, S.M. DFT study of [2.2]-, [3.3]-, and [4.4]paracyclophanes: strain energy, conformations, and rotational barriers. J. Phys. Chem. A 115, 2396–2401 (2011).
Acknowledgements
We would like to thank N. Jura and P. Littlefield (University of California–San Francisco) for providing purified Her3 and J. Kuriyan and K. Engel (University of California–Berkeley) for providing purified EGFR. We also thank N. Jura and K. Shokat for critical reading of the manuscript and A. Cohen for help with X-ray crystallography. This work is supported by a K99/R00 Pathway to Independence Award (1K99GM102288-01) to N.M.L. and a long-standing grant from the US National Institutes of Health (GM27738) to S.G.B.
Author information
Authors and Affiliations
Contributions
N.M.L. designed and performed experiments and wrote the manuscript. S.G.B. designed the experiments and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Results, Supplementary Tables 1 and 2 and Supplementary Figures 1–11. (PDF 2713 kb)
Supplementary Data Set
Structures of protein kinases bound to small-molecule inhibitors in which the inhibitor forms a hydrogen bond to structured water (XLS 36 kb)
Rights and permissions
About this article
Cite this article
Levinson, N., Boxer, S. A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity. Nat Chem Biol 10, 127–132 (2014). https://doi.org/10.1038/nchembio.1404
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1404
This article is cited by
-
Bond-selective fluorescence imaging with single-molecule sensitivity
Nature Photonics (2023)
-
Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
Nature Chemical Biology (2021)
-
Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors
Nature Communications (2020)
-
How to design potent and selective DYRK1B inhibitors? Molecular modeling study
Journal of Molecular Modeling (2019)
-
The role of hydration effects in 5-fluorouridine binding to SOD1: insight from a new 3D-RISM-KH based protocol for including structural water in docking simulations
Journal of Computer-Aided Molecular Design (2019)